0      0


Lunch Activity/Non-CE-Accredited Satellite Symposium: The Role of APPs in Maximizing Patient Outcomes with DARZALEX® and DARZALEX® FASPRO® +Rd in Patients with Newly Diagnosed, Transplant-Ineligible Multiple Myeloma. <br> Janssen Oncology part of the Pharmaceutical Companies of Johnson & Johnson </br><br><i>Seating available on first-come, first-served basis</br></i>


‐ Nov 10, 2023 1:45pm

Mary Steinbach, DNP, APRN